Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Adma Biologics (ADMA) closed at $14.56 in the latest trading session, marking a -3.51% move from the prior day.
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Why Adma Biologics (ADMA) Outpaced the Stock Market Today
Adma Biologics (ADMA) concluded the recent trading session at $15.05, signifying a +2.66% move from its prior day's close.
Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts
In the latest trading session, Adma Biologics (ADMA) closed at $15.91, marking a -1.55% move from the previous day.
ADMA Biologics: Optionality With SG-001 And A Vertically Integrated IG Platform
ADMA's growth remains centered on Asceniv, Bivigam, and NABI-HB. These are its main value drivers today. ADMA Biologics' recent Q2 report showed that the company is working on enhancing its plasma yields by over 20% in IG output. This should help them with margin expansion beginning in 2026. ADMA also reaffirmed its guidance for over $500 million in 2025 revenues and over $625 million by 2026. Its long-term goal remains at over $1.1 billion in sales pre-2030.
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.
ADMA Biologics, Inc. (ADMA) Q2 2025 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Adam S. Grossman - Co-Founder, President, CEO & Director Brad Tade - CFO & Treasurer Skyler Bloom - Senior Director of Business Development & Corporate Strategy Conference Call Participants Anthony Charles Petrone - Mizuho Securities USA LLC, Research Division Gary Jay Nachman - Raymond James & Associates, Inc., Research Division Richard V.
Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.13 per share a year ago.
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Adma Biologics (ADMA) closed at $18.59, marking a +1.81% move from the previous day.
Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts
The latest trading day saw Adma Biologics (ADMA) settling at $18.26, representing a +1.44% change from its previous close.
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
